Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist illustration of a clipboard with a checkmark in a dark color scheme.

Jul 22, 2026

U.S. Payer Friction, Canada Data Fragmentation and U.K. Pathway Delays Expose Same Digital Health Completion Gap

A recent study by Black Book Research highlights significant challenges in digital health workflows across the U.S., Canada, and the U.K., despite advancements in electronic health records (EHRs) and artificial intelligence (AI).The survey, which involved 2,040 clinicians, revealed a persistent gap in clinical loop closure, with a global index score of 44 out of 100. Clinicians reported that while digital systems can initiate tasks, they often require manual follow-up to confirm task completion.
A vaccine vial on a filling station in a pharmaceutical setting.

Jul 22, 2026

Single Use Support speeds design cycle for pharma

Siemens' collaboration with Single Use Support is revolutionizing the pharmaceutical design cycle through innovative technologies aimed at enhancing efficiency in handling sensitive liquids like vaccines.Single Use Support, which operates in Austria and the USA, specializes in single-use technologies for the pharmaceutical sector, focusing on the filling, freezing, storing, and transporting of liquid medicines. By integrating Siemens Xcelerator, particularly Designcenter™ and Teamcenter®, the co
A minimalist illustration of a speech bubble filled with language symbols against a solid indigo background.

Jul 22, 2026

EU releases multilingual AI model for all 24 official languages

The European Commission has launched a new multilingual AI model, the EU-Institutional-LLM, designed to support all 24 official EU languages effectively.This open large language model, developed by the Directorate-General for Translation (DGT), aims to provide balanced performance across the diverse linguistic landscape of the European Union. Unlike many existing models that excel in only a few languages, the EU-Institutional-LLM is tailored to understand the specific legislative and policy cont
A syringe above skin in a clinical setting

Jul 22, 2026

Trinity Biotech (NASDAQ: TRIB) plans equity-backed Latch Medical tie-up in CGM-guided drug delivery

Trinity Biotech has announced a strategic partnership with Latch Medical to advance drug delivery solutions guided by continuous glucose monitoring (CGM) technology. This collaboration aims to integrate Trinity Biotech's CGM+ biosensor platform with Latch Medical's innovative intradermal drug delivery system, potentially enhancing treatment options for metabolic conditions such as diabetes and obesity.The partnership will leverage real-time metabolic data from the CGM+ platform to optimize thera
Close-up of a GPU resource on a workbench in a tech lab

Jul 22, 2026

Microsoft and Mistral expand sovereign AI partnership in Europe

Microsoft has deepened its collaboration with French AI firm Mistral to enhance sovereign AI capabilities in Europe, enabling enterprises to better manage AI deployment and compliance.The expanded partnership integrates Mistral’s AI models with Microsoft’s robust AI platform, facilitating AI operations across various environments—cloud, hybrid, and fully isolated. This initiative is underpinned by a significant multibillion-dollar investment aimed at bolstering European AI infrastructure, partic
Molecular model in a laboratory setting

Jul 22, 2026

R&D Is Investing in AI, Just Not Where It Matters Most

The pharmaceutical industry is poised to invest $25 billion in AI by 2030, driven by the promise of enhanced drug discovery and decision-making. However, a concerning trend is emerging: adoption rates for AI in critical areas of drug discovery, such as generative design and biomarker analysis, are significantly lagging. A primary reason for this disconnect is the fragmented data environment that underpins AI applications, rather than the technology itself.Despite substantial financial commitment
Flat illustration of a split generic drug capsule on a solid background.

Jul 22, 2026

Indian pharma sector seeks stronger US partnership as Trump proposes 100% extra tariff on generic drugs

The Indian pharmaceutical sector is facing significant challenges following President Trump's announcement of steep tariffs on generic drug imports, which could reshape its relationship with the U.S., its largest export market.Beginning August 1, the U.S. will maintain a 0% tariff on generic drug imports for two years, but this will escalate to 100% by August 2028 and potentially 200% thereafter if companies do not establish local manufacturing. This announcement complements earlier tariff plans
A generic drug bottle on a cluttered office desk

Jul 22, 2026

Pharma shares drop as Trump's phased US tariff plan for generic drugs

Pharmaceutical stocks faced a downturn following President Trump's announcement of a phased tariff plan on imported generic drugs, leading to notable declines across major companies.The Nifty Pharma index saw a drop of 1.16%, reversing some of its earlier gains. Notable losses included Lupin, which fell by 3.32%, and other significant players like Piramal Pharma and Aurobindo Pharma, which also experienced declines of over 2%. This trend highlights the immediate market reaction to the proposed t
A minimalist illustration of a DNA strand representing genomic testing.

Jul 22, 2026

Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership

Tempus AI is set to acquire Personalis, a cancer genomics testing firm, in a strategic move valued at approximately $1.5 billion. This acquisition aims to enhance Tempus AI's capabilities in the rapidly expanding minimal residual disease (MRD) testing market, projected to be worth $20 billion.Under the terms of the agreement, Tempus AI will purchase all outstanding shares of Personalis at $16.25 each, reflecting a premium over recent stock prices. The deal is primarily an all-stock transaction,
A minimalist illustration of a train ticket and railway track in dark colors with lime accents.

Jul 22, 2026

Harvard graduate with Indian roots secures $10M for Omio to bring AI multimodal travel to Japan and Southeast Asia

Omio, a Berlin-based multimodal travel platform, has secured a significant $10 million investment from Granite-Integral, aimed at enhancing its presence in Japan and Southeast Asia. This funding will bolster the company’s AI capabilities in Singapore and expand its regional transport partnerships.The investment is strategically timed, coinciding with Omio's recent acquisition of Rail Europe, which is anticipated to enhance its service offerings by enabling the sale of over 22 million rail ticket
Minimalist illustration of a grain package and grain icon

Jul 22, 2026

Restart Life Sciences Unveils U.S. E-Commerce Launch and Strategic Three-Phase Expansion Plan for Holy Crap Foods

Restart Life Sciences Corp. has announced its plan to launch direct-to-consumer e-commerce operations in the U.S. for its subsidiary, Holy Crap Foods, utilizing an AI-enhanced digital platform. The initiative includes a strategic three-phase expansion aimed at optimizing capital deployment while assessing market demand across key regions.The company's phased approach begins with Phase 1, focusing on a digital launch supported by Canadian fulfillment from its British Columbia manufacturing facili
Generic drug packaging in a pharmaceutical factory

Jul 22, 2026

Trump unveils phased tariff plan for generic drugs; pharma exporters from India face long-term US manufacturing push

US President Donald Trump's recent announcement outlines a phased tariff plan targeting imported generic drugs, aiming to boost domestic pharmaceutical manufacturing.The proposed strategy includes a "two-year zero-duty window" for generic medicines, after which tariffs could escalate to 100% and then 200%. This initiative is designed to encourage pharmaceutical companies, particularly those based in India, to establish production facilities in the United States. Currently, India is a major suppl